Vaccinex and Merck KGaA to evaluate VX15/2503 and Avelumab in non-small cell lung cancer

Vaccinex has signed a collaboration agreement with Germany-based Merck KGaA to analyse VX15/2503 in combination with avelumab.

Source: Drug Development Technology - October 9, 2016 Category: Pharmaceuticals Source Type: news